Swiss regulator approves Roche-Regeneron Covid-19 drug
The Swiss medicines agency, Swissmedic, has given the green light to the monoclonal antibody cocktail Ronapreve developed by Roche and Regeneron for use in the treatment and prevention of Covid-19.
Ronapreve, a combination of two monoclonal antibodies (casirivimab and imdevimab), is approved for patients 12 years and up when “oxygen therapy or hospitalisation is not required and there is a high risk of developing a severe form of Covid-19,” Swissmedic said in a statementExternal link.
Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful pathogens such as viruses.
The treatment can also be taken prophylactically when the immune response to Covid-19 vaccination is not adequate. It is the first drug authorised by the Swiss regulator for the prevention of Covid-19 in cases where there is not a sufficient immune response after vaccination due to other diseases or treatments.
Ronapreve is given as a single infusion into a vein or by injection under the skin. The application for the authorisation of the drug, submitted on March 5, didn’t include data on the efficacy of the drug against the Omicron variant.
Since-April, Ronapreve could be administered under the exceptions allowed in the Covid-19 Ordinance 3; an ordinance published by the Federal Council in June 2020 to combat the pandemic. This includes a list of products that can be placed on the market before the authorisation procedure is concluded.
The antibody cocktail has been authorised in several other locations including in Japan and the European Union. It has a conditional approval in the UK and Australia and is available for emergency use in the United States.
More orders
The Federal Office of Public Health (FOPH) has been building up its Covid-19 treatment reserves. On Monday, the FOPH announced that it had signed two additional contracts for more doses of both Ronapreve (4,000 doses) and the monoclonal drug sotrovimab (2,000 doses) developed by GlaxoSmithKline and Vir Biotechnology. The antibody for the latter was discovered by Swiss company Humabs BioMed.
This is on top of the 3,000 doses of each drug the government ordered earlier this year. Contract amounts are confidential for both drugs, according to the FOPH.
External Content
Your subscription could not be saved. Please try again.
Almost finished… We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.
This content was published on
Nemo brought the Eurovision Song Contest to Switzerland with a victory on Saturday evening in Malmö, Sweden. It is Switzerland's third victory in the history of the music contest.
Switzerland abstains from vote on Palestinian bid for full UN membership
This content was published on
On Friday, Switzerland abstained from the vote at the General Assembly on granting the Palestinians new rights at the United Nations (UN).
Protein in abdominal fat could help shape obesity treatment
This content was published on
The study analysed fat cells from different locations in the body, and found that those in the abdomen have unique properties.
North African asylum claims fall after rapid Swiss processing
This content was published on
The accelerated procedure, now out of its test phase, has resulted in a significant drop in applications from North African countries.
This content was published on
The artist's song "The Code" focuses on their journey as a nonbinary individual. It is one of the favourites to win this year's contest.
Swiss pharma reckons with its past, present and future
This content was published on
This is the story of how making drugs helped turn a small, mountainous country into an industry titan, and what the pandemic means for its future.
This content was published on
Swiss biopharma firm Roche has been granted emergency authorisation by US authorities to sell its at-home rapid Covid-19 test starting in January.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.